Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Chia, Jean San ^a   Du, Jia Ling ^a   Hsu, Wei Bin ^a   Sun, Andy ^b   Chiang, Chun Pin ^b   Wang, Won Bo ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; HERBACEOUS AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TIEN HSIEN; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN A; HIF1A PROTEIN, HUMAN; TIEN HSIEN LIQUID; TIEN-HSIEN LIQUID; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER INVASION; CELL MOTION; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TUMOR BURDEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951581527     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-175     Document Type: Article

References (66)

1. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990, 54:159-211. full_text, 1688681.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12(8):895-904. 10.1038/nm1469, 16892035.
3. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005, 1755(1):37-69.
4. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13(8):781-792.
5. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008, 214(3):283-293. 10.1002/path.2282, 18095256.
6. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6(3):227-239. 10.1038/nrc1821, 16498445.
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29(6 Suppl 16):15-18.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407(6801):249-257. 10.1038/35025220, 11001068.
9. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85(12):1301-1307. 10.1007/s00109-007-0281-3, 18026916.
10. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441(7092):437-443. 10.1038/nature04871, 16724055.
11. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995, 270(34):19761-19766. 10.1074/jbc.270.34.19761, 7544346.
12. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2(10):727-739. 10.1038/nrc905, 12360276.
13. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312(5777):1171-1175. 10.1126/science.1125950, 16728631.
14. Lee HJ, Lee EO, Rhee YH, Ahn KS, Li GX, Jiang C, Lu J, Kim SH. An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. Carcinogenesis 2006, 27(12):2455-2463. 10.1093/carcin/bgl104, 16777983.
15. Huerta S, Arteaga JR, Irwin RW, Ikezoe T, Heber D, Koeffler HP. PC-SPES inhibits colon cancer growth in vitro and in vivo. Cancer Res 2002, 62(18):5204-5209.
16. Zhang Z, Wang Y, Yao R, Li J, Yan Y, La Regina M, Lemon WL, Grubbs CJ, Lubet RA, You M. Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene 2004, 23(21):3841-3850. 10.1038/sj.onc.1207496, 15021904.
17. Richardson MA, Straus SE. Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin Oncol 2002, 29(6):531-545. 10.1053/sonc.2002.50002, 12516036.
18. Vickers A. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest 2002, 20(7-8):1069-1079. 10.1081/CNV-120005926, 12449740.
19. Duan YW, Huang Y, Cai LQ, Duan Q, Zhu YS. Inhibition of tumor growth and tumor metastasis by a Chinese herbal formula--ZYD88, in an animal model with metastatic Lewis lung carcinoma. Oncol Rep 2007, 17(6):1391-1397.
20. Buchanan DR, White JD, O'Mara AM, Kelaghan JW, Smith WB, Minasian LM. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience. J Clin Oncol 2005, 23(27):6682-6689. 10.1200/JCO.2005.10.728, 16170176.
21. Sun A, Chia JS, Wang WB, Chiang CP. Immunomodulating effects of "tien-hsien liquid" on peripheral blood mononuclear cells and T-lymphocytes from patients with recurrent aphthous ulcerations. Am J Chin Med 2004, 32(2):221-234. 10.1142/S0192415X04001886, 15315260.
22. Sun A, Chia JS, Wang WB, Chiang CP. "Tien-Hsien liquid" can modulate antigen-stimulated cytokine production by T-cells isolated from patients with recurrent aphthous ulcerations. Am J Chin Med 2005, 33(4):559-571. 10.1142/S0192415X05003168, 16173530.
23. Sun A, Chia JS, Chiang CP, Hsuen SP, Du JL, Wu CW, Wang WB. The chinese herbal medicine Tien-Hsien liquid inhibits cell growth and induces apoptosis in a wide variety of human cancer cells. J Altern Complement Med 2005, 11(2):245-256. 10.1089/acm.2005.11.245, 15865490.
24. Yoshida J, Takamura S, Yamaguchi N, Ren LJ, Chen H, Koshimura S, Suzuki S. Antitumor activity of an extract of Cordyceps sinensis (Berk.) Sacc. against murine tumor cell lines. Jpn J Exp Med 1989, 59(4):157-161.
25. Kuo YC, Lin CY, Tsai WJ, Wu CL, Chen CF, Shiao MS. Growth inhibitors against tumor cells in Cordyceps sinensis other than cordycepin and polysaccharides. Cancer Invest 1994, 12(6):611-615. 10.3109/07357909409023046, 7994596.
26. Bok JW, Lermer L, Chilton J, Klingeman HG, Towers GH. Antitumor sterols from the mycelia of Cordyceps sinensis. Phytochemistry 1999, 51(7):891-898. 10.1016/S0031-9422(99)00128-4, 10423860.
27. Nakamura K, Yamaguchi Y, Kagota S, Kwon YM, Shinozuka K, Kunitomo M. Inhibitory effect of Cordyceps sinensis on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngeneic mice. Jpn J Pharmacol 1999, 79(3):335-341. 10.1254/jjp.79.335, 10230862.
28. Wong BY, Lau BH, Jia TY, Wan CP. Oldenlandia diffusa and Scutellaria barbata augment macrophage oxidative burst and inhibit tumor growth. Cancer Biother Radiopharm 1996, 11(1):51-56. 10.1089/cbr.1996.11.51, 10851520.
29. Sadava D, Ahn J, Zhan M, Pang ML, Ding J, Kane SE. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother Pharmacol 2002, 49(4):261-266. 10.1007/s00280-002-0427-5, 11914903.
30. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12(1):53-63. 10.1002/stem.5530120110, 8142920.
31. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999, 1(1):60-67. 10.1038/9035, 10559866.
32. Ohsawa T, Yukawa M, Takao C, Murayama M, Bando H. Studies on constituents of fruit body of Polyporus umbellatus and their cytotoxic activity. Chem Pharm Bull (Tokyo) 1992, 40(1):143-147.
33. You JS, Hau DM, Chen KT, Huang HF. Combined effects of chuling (Polyporus umbellatus) extract and mitomycin C on experimental liver cancer. Am J Chin Med 1994, 22(1):19-28. 10.1142/S0192415X94000048, 8030616.
34. Lau BH, Ruckle HC, Botolazzo T, Lui PD. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother 1994, 9(2):153-161.
35. Kurashige S, Akuzawa Y, Endo F. Effects of astragali radix extract on carcinogenesis, cytokine production, and cytotoxicity in mice treated with a carcinogen, N-butyl-N'-butanolnitrosoamine. Cancer Invest 1999, 17(1):30-35.
36. Cui R, He J, Wang B, Zhang F, Chen G, Yin S, Shen H. Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother Pharmacol 2003, 51(1):75-80. 10.1007/s00280-002-0532-5, 12497209.
37. Lin J, Dong HF, Oppenheim JJ, Howard OM. Effects of astragali radix on the growth of different cancer cell lines. World J Gastroenterol 2003, 9(4):670-673.
38. Keum YS, Park KK, Lee JM, Chun KS, Park JH, Lee SK, Kwon H, Surh YJ. Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett 2000, 150(1):41-48. 10.1016/S0304-3835(99)00369-9, 10755385.
39. Shin HR, Kim JY, Yun TK, Morgan G, Vainio H. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control 2000, 11(6):565-576. 10.1023/A:1008980200583, 10880039.
40. Kim JY, Lee KW, Kim SH, Wee JJ, Kim YS, Lee HJ. Inhibitory effect of tumor cell proliferation and induction of G2/M cell cycle arrest by panaxytriol. Planta Med 2002, 68(2):119-122. 10.1055/s-2002-20240, 11859460.
41. Hu K, Kobayashi H, Dong A, Jing Y, Iwasaki S, Yao X. Antineoplastic agents. III: Steroidal glycosides from Solanum nigrum. Planta Med 1999, 65(1):35-38. 10.1055/s-1999-13958, 10083842.
42. Zheng YT, Zhang WF, Ben KL, Wang JH. In vitro immunotoxicity and cytotoxicity of trichosanthin against human normal immunocytes and leukemia-lymphoma cells. Immunopharmacol Immunotoxicol 1995, 17(1):69-79. 10.3109/08923979509052721, 7759776.
43. Zhang C, Gong Y, Ma H, An C, Chen D, Chen ZL. Reactive oxygen species involved in trichosanthin-induced apoptosis of human choriocarcinoma cells. Biochem J 2001, 355(Pt 3):653-661. 1221780, 11311127.
44. Qiu G, Zhang M, Yang Y. [The antitumour activity of total saponin of Clematis chinensis]. Zhong Yao Cai 1999, 22(7):351-353.
45. Agarwal R, Wang ZY, Mukhtar H. Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. Nutr Cancer 1991, 15(3-4):187-193. 10.1080/01635589109514126, 1907733.
46. Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA, DiPaola RS. Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem 2002, 50(4):677-684. 10.1021/jf010774e, 11829627.
47. Zhang W, Yang J, Chen J, Hou Y, Han X. Immunomodulatory and antitumour effects of an exopolysaccharide fraction from cultivated Cordyceps sinensis (Chinese caterpillar fungus) on tumour-bearing mice. Biotechnol Appl Biochem 2005, 42(Pt 1):9-15.
48. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001, 16(Suppl):S28-37.
49. Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, Azuma I. Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol Pharm Bull 1994, 17(5):635-639.
50. Yamazaki S, Morita T, Endo H, Hamamoto T, Baba M, Joichi Y, Kaneko S, Okada Y, Okuyama T, Nishino H, et al. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett 2002, 183(1):23-30. 10.1016/S0304-3835(02)00113-1, 12049811.
51. Kobayashi M, Fujita K, Katakura T, Utsunomiya T, Pollard RB, Suzuki F. Inhibitory effect of glycyrrhizin on experimental pulmonary metastasis in mice inoculated with B16 melanoma. Anticancer Res 2002, 22(6C):4053-4058.
52. Gupta S, Zhang D, Yi J, Shao J. Anticancer activities of Oldenlandia diffusa. J Herb Pharmacother 2004, 4(1):21-33. 10.1300/J157v04n01_03, 15273074.
53. Kobayashi S, Miyamoto T, Kimura I, Kimura M. Inhibitory effect of isoliquiritin, a compound in licorice root, on angiogenesis in vivo and tube formation in vitro. Biol Pharm Bull 1995, 18(10):1382-1386.
54. Xu Y, Pan RL, Chang Q, Qin M, Liu Y, Tang JT. [Experimental study of Solanum nigrum on inhibiting angiogenesis in chick chorioallantoic membrane]. Zhongguo Zhong Yao Za Zhi 2008, 33(5):549-552.
55. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52(11):2745-2756. 10.1172/JCI107470, 302542, 4355998.
56. Grant DS, Kinsella JL, Fridman R, Auerbach R, Piasecki BA, Yamada Y, Zain M, Kleinman HK. Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol 1992, 153(3):614-625. 10.1002/jcp.1041530324, 1280280.
57. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280(43):36529-36540. 10.1074/jbc.M503111200, 1351057, 16127174.
58. Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B, Linder S. ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis 1999, 17(8):649-654. 10.1023/A:1006741228402, 10919709.
59. Zhu X, Jiang J, Shen H, Wang H, Zong H, Li Z, Yang Y, Niu Z, Liu W, Chen X, et al. Elevated beta1,4-galactosyltransferase I in highly metastatic human lung cancer cells. Identification of E1AF as important transcription activator. J Biol Chem 2005, 280(13):12503-12516. 10.1074/jbc.M413631200, 15611127.
60. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005, 26(4):741-751. 10.1093/carcin/bgi027, 15661802.
61. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253(1-2):269-285. 10.1023/A:1026028303196, 14619979.
62. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998, 55(1):29-42. 10.1006/mvre.1997.2056, 9473407.
63. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10(1):39-49. 10.2174/1381612043453559, 14754404.
64. Viala E, Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann N Y Acad Sci 2004, 1030:208-218. 10.1196/annals.1329.027, 15659800.
65. Milanini-Mongiat J, Pouyssegur J, Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002, 277(23):20631-20639. 10.1074/jbc.M201753200, 11904305.
66. Wen CC, Cheng SA, Hsuen SP, Huang YL, Kuo ZK, Lee HF, Kuo CH, Du JL, Wang WB. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res 2006, 66(11):5847-5857. 10.1158/0008-5472.CAN-05-2109, 16740724.